摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(7-nitro-1H-inden-3-yl)-1H-imidazole-1-carboxylate | 258528-40-4

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(7-nitro-1H-inden-3-yl)-1H-imidazole-1-carboxylate
英文别名
1,1-Dimethylethyl 4-(7-nitro-1H-inden-3-yl)-1H-imidazole-1-carboxylate;tert-butyl 4-(4-nitro-3H-inden-1-yl)imidazole-1-carboxylate
tert-butyl 4-(7-nitro-1H-inden-3-yl)-1H-imidazole-1-carboxylate化学式
CAS
258528-40-4
化学式
C17H17N3O4
mdl
——
分子量
327.34
InChiKey
GSQNPVAJZVZUPE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    89.9
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 4-(7-nitro-1H-inden-3-yl)-1H-imidazole-1-carboxylate 在 palladium on activated charcoal 氢气 作用下, 以 乙酸乙酯 为溶剂, 反应 16.0h, 以91%的产率得到tert-butyl 4-(4-amino-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-1-carboxylate
    参考文献:
    名称:
    Synthesis and Structure−Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α1A-Adrenoceptor Agonist
    摘要:
    Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.
    DOI:
    10.1021/jm030551a
  • 作为产物:
    参考文献:
    名称:
    Synthesis and Structure−Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α1A-Adrenoceptor Agonist
    摘要:
    Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.
    DOI:
    10.1021/jm030551a
点击查看最新优质反应信息

文献信息

  • 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
    申请人:——
    公开号:US20030073850A1
    公开(公告)日:2003-04-17
    Compounds of formula I 1 are useful in treating diseases prevented by or ameliorated with &agr; 1A agonists. Also disclosed are &agr; 1A agonist compositions and a method of activating &agr; 1 adrenoceptors in a mammal.
    公式I的化合物在治疗由&agr; 1A激动剂预防或改善的疾病中很有用。还公开了&agr; 1A激动剂组合物和在哺乳动物中激活&agr; 1肾上腺素受体的方法。
  • US6503935B1
    申请人:——
    公开号:US6503935B1
    公开(公告)日:2003-01-07
  • Synthesis and Structure−Activity Studies on <i>N</i>-[5-(1<i>H</i>-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α<sub>1A</sub>-Adrenoceptor Agonist
    作者:Robert J. Altenbach、Albert Khilevich、Teodozyj Kolasa、Jeffrey J. Rohde、Pramila A. Bhatia、Meena V. Patel、Xenia B. Searle、Fan Yang、William H. Bunnelle、Karin Tietje、Erol K. Bayburt、William A. Carroll、Michael D. Meyer、Rodger Henry、Steven A. Buckner、Jane Kuk、Anthony V. Daza、Ivan V. Milicic、John C. Cain、Chae H. Kang、Lynne M. Ireland、Tracy L. Carr、Thomas R. Miller、Arthur A. Hancock、Masaki Nakane、Timothy A. Esbenshade、Michael E. Brune、Alyssa B. O'Neill、Donna M. Gauvin、Sweta P. Katwala、Mark W. Holladay、Jorge D. Brioni、James P. Sullivan
    DOI:10.1021/jm030551a
    日期:2004.6.1
    Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.
查看更多

同类化合物

马来酸二甲茚定 螺[茚-1,4’-哌啶]盐酸盐 螺[茚-1,4-哌啶] 螺[1H-茚-1,4-哌啶]-3-羧酸盐酸盐 螺[1H-茚-1,4-哌啶]-1,3-二羧酸,1,1-二甲基乙酯 螺[1,3-二氧戊环-2,1'-茚] 茚洛秦 茚旦醇 茚并[2,1-a]茚 茚屈林 茚-2,3-二羧酸 苯酚,2-(1H-茚-3-基)- 苯茚达明酒石酸盐 苯茚胺 苯基亚甲基双(三环己基磷)二氯化钌 膦,1H-茚-1-基二苯基- 硬树脂 硫化舒林酸 硫化舒林酸 盐酸茚诺洛尔 盐酸茚洛秦 盐酸苯二胺 甲茚 甲基3-氨基-1H-茚-2-羧酸酯 甲基3-氨基-1-氰基-1-苯基-1H-茚-2-羧酸酯 甲基1-氧代-2-苯基-1H-茚-3-基碳酸酯 氨甲酸,[(1S)-1-甲基-2-(硝基氧代)乙基]-,1,1-二甲基乙基酯(9CI) 异苯茚达明 尿苷,2'-脱氧-5-(2-羟基乙基)-,3',5'-二(4-甲基苯酸酯)(9CI) 外消旋-N-去甲基二甲茚定 四氢荧蒽 四-1H-茚-1-ylstannane 吡喃达明盐酸盐 吡喃达明 叔-丁基6-甲基螺[茚并-1,4-哌啶]-1-甲酸基酯 叔-丁基6-氯螺[茚并-1,4-哌啶]-1-甲酸基酯 亚乙基二(4,5,6,7-四氢-1-茚基)二甲基锆(IV) 二茚并[1,2-b:2,1-e]吡啶-10,12-二酮,5,11-二氢-5-甲基- 二甲茚定 二甲基[二(2-甲基-1H-茚-1-基)]硅烷 二甲基-(2-吗啉-4-基-茚-1-亚基甲基)-胺 二环己基[2-(2,4,6-三甲基苯基)-1H-茚-3-基]膦 二-1H-茚-1-基-二甲基硅烷 三(异丙氧基)膦(3-苯基-1H-茚-1-基)[1,3-双(2,4,6-三甲基苯基)-4,5-二氢咪唑-2-基]钌(II)二氯化物 三乙基-茚-1-基-硅烷 rac-乙烯双(1-茚基)二氯化锆 [4-(4-叔丁基苯基)-2-异丙基-1H-茚-1-基][4-(4-叔丁基苯基)-2-甲基-1H-茚-1-基]二甲基硅烷 [(1Z)-5-氟-2-甲基-1-(3-噻吩基亚甲基)-1H-茚-3-基]乙酸 N,N-二甲基-3-[(1S)-1-(2-吡啶基)乙基]-1H-茚满-2-乙胺马来酸酯